DK0584552T3 - Chlorophyl- og bakteriochlorophylderivater, deres fremstilling og farmaceutiske sammensætninger omfattende dem - Google Patents

Chlorophyl- og bakteriochlorophylderivater, deres fremstilling og farmaceutiske sammensætninger omfattende dem

Info

Publication number
DK0584552T3
DK0584552T3 DK93111942T DK93111942T DK0584552T3 DK 0584552 T3 DK0584552 T3 DK 0584552T3 DK 93111942 T DK93111942 T DK 93111942T DK 93111942 T DK93111942 T DK 93111942T DK 0584552 T3 DK0584552 T3 DK 0584552T3
Authority
DK
Denmark
Prior art keywords
derivatives
chl
conjugates
bchl
bacteriochlorophyl
Prior art date
Application number
DK93111942T
Other languages
Danish (da)
English (en)
Inventor
Avigdor Scherz
Yoram Salomon
Leszek Fiedor
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK0584552T3 publication Critical patent/DK0584552T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036Porphyrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052Small organic molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68Melanocyte-stimulating hormone [MSH]
    • C07K14/685Alpha-melanotropin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795Porphyrin- or corrin-ring-containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK93111942T 1992-07-26 1993-07-26 Chlorophyl- og bakteriochlorophylderivater, deres fremstilling og farmaceutiske sammensætninger omfattende dem DK0584552T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL102645A IL102645A (en) 1992-07-26 1992-07-26 Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
DK0584552T3 true DK0584552T3 (da) 2001-02-05

Family

ID=11063865

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93111942T DK0584552T3 (da) 1992-07-26 1993-07-26 Chlorophyl- og bakteriochlorophylderivater, deres fremstilling og farmaceutiske sammensætninger omfattende dem

Country Status (16)

Country Link
US (3) US5726169A (de)
EP (1) EP0584552B1 (de)
JP (1) JP3612343B2 (de)
CN (1) CN1040212C (de)
AT (1) ATE196850T1 (de)
AU (1) AU674315B2 (de)
CA (1) CA2101227C (de)
DE (1) DE69329538T2 (de)
DK (1) DK0584552T3 (de)
ES (1) ES2153367T3 (de)
GR (1) GR3035195T3 (de)
HU (1) HU221186B1 (de)
IL (1) IL102645A (de)
PL (2) PL173150B1 (de)
PT (1) PT584552E (de)
ZA (1) ZA935310B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147195A (en) * 1993-07-26 2000-11-14 Yeda Research And Development Co., Ltd. Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
IL116126A0 (en) 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
GB9625895D0 (en) * 1996-12-13 1997-01-29 Riley Patrick A Novel compound useful as therapeutic agents and assay reagents
CN1074771C (zh) * 1996-12-30 2001-11-14 中国科学院长春应用化学研究所 聚合物载体茂金属催化剂的制备
US6066628A (en) * 1997-01-09 2000-05-23 Emory University Non-iron metalloporphyrins and methods of use
DE19731741A1 (de) * 1997-07-23 1999-01-28 Deutsches Krebsforsch Konjugat zur Unterscheidung von krankhaftem und gesundem Gewebe
US6652836B2 (en) 1998-10-15 2003-11-25 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
US6299860B1 (en) 1998-10-15 2001-10-09 Fluoro Probe, Inc. Method for viewing diseased tissue located within a body cavity
US6284223B1 (en) * 1998-10-15 2001-09-04 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
PT1137411E (pt) * 1998-12-09 2007-02-28 Yeda Res & Dev Processo para inibir respostas ao etileno em plantas
US7045117B2 (en) * 1999-12-01 2006-05-16 Yeda Research And Development Co. Ltd. Method for tumor diagnosis comprising administering of palladium-substituted bacteriochlorophyll derivatives
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
WO2001051087A2 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
US20020169107A1 (en) * 2001-01-19 2002-11-14 Mallinckrodt Inc. Novel aromatic azides for type I phototherapy
US7235685B2 (en) 2001-07-03 2007-06-26 Mallinckrodt, Inc. Aromatic sulfenates for type I phototherapy
AU7570201A (en) * 2000-07-26 2002-02-05 Riley Patrick Anthony Phenylethylamine derivatives and their use in the treatment of melanoma
WO2002013820A1 (en) * 2000-08-11 2002-02-21 Ceramoptec Industries, Inc. Photosensitizing ointment
AU2006200164B2 (en) * 2001-04-09 2007-03-08 Oncofluor, Inc. Method for viewing tumor tissue located within a body cavity
IL148921A0 (en) * 2002-03-26 2002-09-12 Peptor Ltd Photo active backbone cyclized somatostatin analogs for optical imaging and photodynamic therapy
EP2401962A1 (de) 2002-05-08 2012-01-04 Yeda Research And Development Co., Ltd. Sensibilisiertes Online-BOLD-MRI-Abbildungsverfahren
IL152900A0 (en) * 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
GB0323358D0 (en) * 2003-10-06 2003-11-05 Green Grass Design Ltd Novel compounds and processes
CA2569675C (en) 2004-06-07 2015-03-17 Yeda Research And Development Co. Ltd Cationic bacteriochlorophyll derivatives and uses thereof
US7947827B2 (en) * 2006-06-30 2011-05-24 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Pharmaceutical formulation comprising a metaloporphyrin and method for its purification and use
DK2061512T3 (da) * 2006-08-23 2020-01-20 Yeda Res & Dev Konjugater af rgd-peptider og (bakterie)chlorophylfotosensibilisatorer samt anvendelser deraf
US9957293B2 (en) 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
WO2009039207A1 (en) 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
FR2924021B1 (fr) * 2007-11-27 2010-08-13 Du Vernet Michele Eymard Composition pour le traitement de la peau par therapie photodynamique
EP2244787A1 (de) * 2008-01-28 2010-11-03 Yeda Research And Development Company Ltd. Fotodynamisches therapiesystem mit endoskopabbildung und einsatzverfahren
EP2259794A1 (de) * 2008-02-22 2010-12-15 Clinuvel Pharmaceuticals Limited Verfahren zur behandlung von lichtempfindlichkeit und phototoxizität
MX2010009530A (es) 2008-02-27 2010-11-30 Yeda Res & Dev Conjugados de rgd-(bacterio) clorofila para terapia fotodinámica y formación de imágenes de tumores necróticos.
JP6215203B2 (ja) 2011-08-23 2017-10-18 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co. Ltd 眼疾患および障害の治療用の(バクテリオ)クロロフィル光増感剤
ES2764090T3 (es) 2012-12-19 2020-06-02 Univ New York State Res Found Composiciones y procedimiento para la liberación activada por la luz de materiales de nanovesículas
KR20160068701A (ko) * 2013-06-05 2016-06-15 하페치 파하드 유효성분을 광활성화시키는 것을 포함하는 조성물을 도포하는 방법 및 투여 방식을 가진 약제학적 조성물
RU2536116C1 (ru) * 2013-07-25 2014-12-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ фотодинамической обработки склерального ложа после эндорезекции внутриглазного новообразования
RU2536109C1 (ru) * 2013-07-25 2014-12-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ комбинированной обработки склерального ложа после эндорезекции внутриглазного новообразования
SG10201506686WA (en) * 2015-08-24 2017-03-30 Agency Science Tech & Res Conjugates
CN111171030B (zh) * 2018-11-12 2022-11-22 浙江海正药业股份有限公司 细菌叶绿素衍生物及其制备方法
CN115093422B (zh) * 2022-06-15 2023-06-20 西北工业大学 一种基于代谢标记策略的新型光敏剂及其制备方法和应用
CN116585530B (zh) * 2023-05-05 2024-02-02 暨南大学 一种高效产氧的叶绿体复合水凝胶及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) * 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4977177A (en) * 1985-04-30 1990-12-11 Nippon Petrochemicals Company, Ltd. Tetrapyrrole polyaminomonocarboxylic acid therapeutic agents
HU204856B (en) * 1987-08-12 1992-02-28 Orszagos Mueszaki Fejlesztesi Process for releasing cell mixtures and tissues from undesired populations and for producing monoclonal antibody - hematoporphyrin conjugates
US4876190A (en) * 1987-10-21 1989-10-24 Becton Dickinson & Company Peridinin-chlorophyll complex as fluorescent label
DE68928607T2 (de) * 1988-07-14 1998-07-23 Toyohakka Kogyo K K Porphyrinderivate
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5567687A (en) * 1989-03-06 1996-10-22 University Of Texas Texaphyrins and uses thereof
US5171741A (en) * 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5238940A (en) * 1990-03-22 1993-08-24 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
DE4121876A1 (de) * 1991-07-02 1993-01-14 Scheer Hugo Modifizierte bakteriochlorophylle, verfahren zu ihrer herstellung und ihre verwendung
US5330741A (en) * 1992-02-24 1994-07-19 The Regents Of The University Of California Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors

Also Published As

Publication number Publication date
CN1040212C (zh) 1998-10-14
PL173150B1 (pl) 1998-01-30
CN1088210A (zh) 1994-06-22
US5955585A (en) 1999-09-21
EP0584552B1 (de) 2000-10-11
HU221186B1 (en) 2002-08-28
JPH0733772A (ja) 1995-02-03
AU4214893A (en) 1994-01-27
JP3612343B2 (ja) 2005-01-19
AU674315B2 (en) 1996-12-19
ES2153367T3 (es) 2001-03-01
US5726169A (en) 1998-03-10
EP0584552A2 (de) 1994-03-02
US5650292A (en) 1997-07-22
HU9302149D0 (en) 1993-10-28
GR3035195T3 (en) 2001-04-30
EP0584552A3 (en) 1994-08-17
IL102645A (en) 1998-02-22
ATE196850T1 (de) 2000-10-15
PL173128B1 (pl) 1998-01-30
PT584552E (pt) 2001-04-30
PL299803A1 (en) 1994-02-07
ZA935310B (en) 1994-02-11
DE69329538T2 (de) 2001-06-07
CA2101227A1 (en) 1994-01-27
CA2101227C (en) 2002-11-12
DE69329538D1 (de) 2000-11-16
HUT64949A (en) 1994-03-28
IL102645A0 (en) 1993-01-14

Similar Documents

Publication Publication Date Title
DK0584552T3 (da) Chlorophyl- og bakteriochlorophylderivater, deres fremstilling og farmaceutiske sammensætninger omfattende dem
ES2736505T3 (es) Nuevo conjugado estable de anticuerpo-fármaco, método de preparación y uso del mismo
US6217873B1 (en) Polyoxime compounds and their preparation
WO1988000837A2 (en) Advanced anticancer therapy and cytotoxic medicaments for its implementation
DK0662827T3 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
RU2009130954A (ru) Применение белков теплового шока для улучшения терапевтического эффекта невакционного лечебного воздействия
NO891711L (no) Hiv env-kodet peptid som er istand til aa fremkalle hiv-inhiberende antistoffer i pattedyr.
CY1105701T1 (el) Μεθοδος δια την παρασκευη ενος ενεσιμου φαρμακευτικου σκευασματος
HUT70471A (en) Antitumor imunoconjugates, method for producing them, and pharmaceutical compositions containing the conjugates
CY1107047T1 (el) Παραγωγα δολαστατινης 15
DE602006017667D1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
DK1246826T3 (da) Chlorophyl- og bakteriochlorophylestere, deres fremstilling og farmaceutiske præparater omfattende disse estere
RU94024566A (ru) Способ модификации, способ обеспечения связывания белка с антителом, фармацевтические композиции, способ диагностики
NZ504938A (en) Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen
KR20180081494A (ko) 암의 표적화 치료를 위한 광역학 치료제의 합성 및 조성물
EP2046813B1 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel
US6663869B1 (en) Polyoxime compounds and their preparation
WO1991000111A1 (en) Targetting agents
AU635721B2 (en) Targetting agents
CN115814111A (zh) 一种近红外荧光adc免疫制剂及其制备方法与应用
ES2326530T3 (es) Citocinas modificadas para su utilizacion en la terapia del cancer.
DE60019725D1 (de) Verwendung eines mit dem peptid "elagigiltv" assoziierten enterobakterien-proteins ompa zur behandlung von melanomen
ES2360203T3 (es) Ligación química "seudo"- natural.
DK549589A (da) Neoglycoproteiner, deres fremstilling og anvendelse
DK0584118T3 (da) Nyt konjugat, bestående af et glycoprotein og en nucleinsyrebindende substans